A conditional error function approach for adaptive enrichment designs with continuous endpoints
暂无分享,去创建一个
[1] M. Humbert,et al. Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.
[2] Martin Posch,et al. Design and estimation in clinical trials with subpopulation selection , 2018, Statistics in medicine.
[3] C. Jennison,et al. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.
[4] Martin Posch,et al. Adaptive designs for subpopulation analysis optimizing utility functions , 2014, Biometrical journal. Biometrische Zeitschrift.
[5] W. Lehmacher,et al. Adaptive Sample Size Calculations in Group Sequential Trials , 1999, Biometrics.
[6] Tim Friede,et al. Aspects of Modernizing Drug Development Using Clinical Scenario Planning and Evaluation , 2010 .
[7] K. Gabriel,et al. SIMULTANEOUS TEST PROCEDURES-SOME THEORY OF MULTIPLE COMPARISONS' , 1969 .
[8] L Di Scala,et al. Time‐to‐event analysis with treatment arm selection at interim , 2011, Statistics in medicine.
[9] P. Bauer,et al. Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.
[10] S. Pocock. Group sequential methods in the design and analysis of clinical trials , 1977 .
[11] M. Gladwin,et al. Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[12] T. Friede,et al. A conditional error function approach for subgroup selection in adaptive clinical trials , 2012, Statistics in medicine.
[13] K. Gabriel,et al. On closed testing procedures with special reference to ordered analysis of variance , 1976 .
[14] H. Schäfer,et al. A general statistical principle for changing a design any time during the course of a trial , 2004, Statistics in medicine.
[15] Bart Spiessens,et al. Adjusted significance levels for subgroup analyses in clinical trials. , 2010, Contemporary clinical trials.
[16] H. Schäfer,et al. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches , 2001, Biometrics.
[17] Nigel Stallard,et al. Sequential designs for phase III clinical trials incorporating treatment selection , 2003, Statistics in medicine.
[18] C. Mehta,et al. Design and monitoring of multi‐arm multi‐stage clinical trials , 2017, Biometrics.
[19] T. Friede,et al. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review , 2016, Journal of biopharmaceutical statistics.
[20] Michael Rosenblum,et al. Group sequential designs with prospectively planned rules for subpopulation enrichment , 2016, Statistics in medicine.
[21] Sue-Jane Wang,et al. Modification of Sample Size in Group Sequential Clinical Trials , 1999, Biometrics.
[22] Tim Friede,et al. Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection , 2014, Journal of biopharmaceutical statistics.
[23] M. Landray,et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. , 2016, European heart journal.
[24] S. Day. Data monitoring committees in clinical trials: best practice, complexities and considerations , 2015 .
[25] Gernot Wassmer,et al. Designing Issues in Confirmatory Adaptive Population Enrichment Trials , 2015, Journal of Biopharmaceutical Statistics.
[26] B. Turnbull,et al. Group Sequential Methods , 1999 .
[27] G. Wassmer,et al. Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker , 2018, Statistical methods in medical research.
[28] Horst Olschewski,et al. Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[29] Frank Bretz,et al. Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: Applications and Practical Considerations , 2006, Biometrical journal. Biometrische Zeitschrift.
[30] C. Dunnett. A Multiple Comparison Procedure for Comparing Several Treatments with a Control , 1955 .
[31] M Kieser,et al. Combining different phases in the development of medical treatments within a single trial. , 1999, Statistics in medicine.
[32] Tim Friede,et al. A group‐sequential design for clinical trials with treatment selection , 2008, Statistics in medicine.
[33] M. Kieser,et al. Point estimation in adaptive enrichment designs , 2017, Statistics in medicine.
[34] Frank Bretz,et al. Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts , 2006, Biometrical journal. Biometrische Zeitschrift.
[35] Michael Rosenblum,et al. Multiple testing procedures for adaptive enrichment designs: combining group sequential and reallocation approaches. , 2016, Biostatistics.
[36] Tim Friede,et al. A Comparison of Methods for Adaptive Treatment Selection , 2008, Biometrical journal. Biometrische Zeitschrift.
[37] M. Rahbar,et al. Advancing clinical trial design in pulmonary hypertension , 2013, Pulmonary circulation.
[38] Nigel Stallard,et al. Estimation after subpopulation selection in adaptive seamless trials , 2015, Statistics in medicine.
[39] P. Bauer,et al. The reassessment of trial perspectives from interim data—a critical view , 2006, Statistics in medicine.
[40] Tim Friede,et al. Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies , 2018, Statistical methods in medical research.
[41] M. Posch,et al. Optimizing Trial Designs for Targeted Therapies , 2016, PloS one.
[42] T. Fleming,et al. End points and clinical trial design in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[43] Nigel Stallard,et al. An Adaptive Group Sequential Design for Phase II/III Clinical Trials that Select a Single Treatment From Several , 2005, Journal of biopharmaceutical statistics.
[44] Martin Posch,et al. Optimized adaptive enrichment designs , 2017, Statistical methods in medical research.
[45] Frank Bretz,et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.
[46] Cyrus Mehta,et al. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints , 2014, Statistics in medicine.
[47] Frank Bretz,et al. Adaptive Dunnett tests for treatment selection , 2008, Statistics in medicine.
[48] J. Whitehead,et al. A generalized Dunnett Test for Multi-arm Multi-stage Clinical Studies with Treatment Selection , 2012 .
[49] M. Yeager,et al. Proteomics of pulmonary hypertension: Could personalized profiles lead to personalized medicine? , 2015, Proteomics. Clinical applications.
[50] W. Brannath,et al. Recursive Combination Tests , 2002 .
[51] J. Loyd. Pulmonary arterial hypertension: insights from genetic studies. , 2011, Proceedings of the American Thoracic Society.